[20200602]LSB10483_测试测试(阶段)1-2-3:潜在2019冠状病毒疾病疫苗临床试验的法律考虑.pdf

上传人:任我行 文档编号:29378 上传时间:2022-06-24 发布时间:2020-06-02 格式:PDF 页数:5 大小:708.49KB
下载 相关 举报
[20200602]LSB10483_测试测试(阶段)1-2-3:潜在2019冠状病毒疾病疫苗临床试验的法律考虑.pdf_第1页
第1页 / 共5页
[20200602]LSB10483_测试测试(阶段)1-2-3:潜在2019冠状病毒疾病疫苗临床试验的法律考虑.pdf_第2页
第2页 / 共5页
[20200602]LSB10483_测试测试(阶段)1-2-3:潜在2019冠状病毒疾病疫苗临床试验的法律考虑.pdf_第3页
第3页 / 共5页
[20200602]LSB10483_测试测试(阶段)1-2-3:潜在2019冠状病毒疾病疫苗临床试验的法律考虑.pdf_第4页
第4页 / 共5页
[20200602]LSB10483_测试测试(阶段)1-2-3:潜在2019冠状病毒疾病疫苗临床试验的法律考虑.pdf_第5页
第5页 / 共5页
亲,该文档总共5页,全部预览完了,如果喜欢就下载吧!
资源描述

1、CRS Legal Sidebar Prepared for Members and Committees of Congress Legal SidebarLegal Sidebari i Testing, Testing, (Phase) 1-2-3: Legal Considerations for Clinical Trials of Potential COVID-19 Vaccines June 2, 2020 In the race to develop a Coronavirus Disease 2019 (COVID-19) vaccine, several pharmace

2、utical companies, governments, and educational institutions around the world have begun testing their potential COVID-19 vaccines in clinical trials. Clinical trials are used to assess whether a new pharmaceutical product, such as a vaccine, is safe for humans and effective in achieving its intended

3、 purpose. Companies must generally test new pharmaceutical products on humans through clinical trials to obtain U.S. Food and Drug Administration (FDA) approval to market the product. But using human subjects to test these novel products exposes them to unknown health and safety risks, raising ethic

4、al considerations for FDA and for the sponsors and Institutional Review Boards (IRBs) overseeing the investigations. These stakeholderssponsors, IRBs, and FDAaim to balance the need to ensure that the product is safe and effective against the desire to bring the product to market quickly, tensions t

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告